Evidence map›Paper›PMID 37449673›Full record

ReviewImmunological reviews2023

Applications of CRISPR technology in cellular immunotherapy.

Xiaoyu Zhou, Paul A Renauer, Liqun Zhou, Shao-Yu Fang, Sidi Chen

Open access · bronzeAbstract readReview
In one paragraph

Review in Immunological reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Golden age of immunoengineering.Immunological reviews · 2023
    Article
  8. Applications of CRISPR screening to lung cancer treatment.Frontiers in cell and developmental biology · 2023
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Xiaoyu ZhouDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA.
Paul A RenauerDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA.
Liqun ZhouDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA.
Shao-Yu FangDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA.
Sidi ChenDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0002-3819-5005
Yale Cancer Center · US

Funding

PREDOCTORAL TRAINING PROGRAM IN GENETICST32GM007499 · NIGMS · YALE UNIVERSITY · PI CARLSON, JOHN R, REINKE, VALERIE J · 1985 to 2022
$13.9M
(PQ4) Novel tools for in vivo study of genetic interactions in cancer progressionR01CA231112 · NCI · YALE UNIVERSITY · PI CHEN, SIDI · 2018 to 2022
$3.0M
High-throughput in vivo genetics for immunotherapy target discoveryDP2CA238295 · NCI · YALE UNIVERSITY · PI CHEN, SIDI · 2018 to 2018
$2.5M
Advanced development of composite gene delivery and CAR engineering systemsR33CA281702 · NCI · YALE UNIVERSITY · PI CHEN, SIDI · 2023 to 2025
$1.2M
Cancer Research Institute CRI4964NCI NIH HHS DP2 CA238295NCI NIH HHS R01 CA231112NCI NIH HHS R33 CA281702NIGMS NIH HHS T32 GM007499NIH HHS DP2CA238295NIH HHS R01CA231112NIH HHS T32GM007499
6 · The paper itself

Abstract

CRISPR technology has transformed multiple fields, including cancer and immunology. CRISPR-based gene editing and screening empowers direct genomic manipulation of immune cells, opening doors to unbiased functional genetic screens. These screens aid in the discovery of novel factors that regulate and reprogram immune responses, offering novel drug targets. The engineering of immune cells using CRISPR has sparked a transformation in the cellular immunotherapy field, resulting in a multitude of ongoing clinical trials. In this review, we discuss the development and applications of CRISPR and related gene editing technologies in immune cells, focusing on functional genomics screening, gene editing-based cell therapies, as well as future directions in this rapidly advancing field.

Indexed as

Gene EditingNeoplasmsGenomicsHumansImmunotherapyTechnologyCRISPRgenomic perturbationimmune engineeringT-cell therapy

Identifiers

PMID37449673
PMCPMC10787818
OpenAlexW4384298488

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.